Clinical Trial

HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-05-21
Trial Details
NCT Number NCT07587034
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Affiliated Hospital of Nantong University, Nantong First People's Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Shandong Public Health Clinical Center, Shanghai Xuhui Hospital, The fifth Hospital Affiliated To WZMU
Conditions Liver Cancer
Enrollment 315 participants
Start Date 2026-06
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-20